Nivolumab/relatlimab-associated cutaneous immune-related adverse events in patients treated for advanced melanoma: Supplemental file

Supplementary tables I (multivariable analysis of patient characteristics associated with developing cirAEs on nivolumab-relatlimab) and II (choice of therapy for the management of first, second, and third cirAEs)